Cue Biopharma Depreciation And Amortization Over Time
| CUE Stock | USD 1.01 0.01 0.98% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Cue Biopharma Performance and Cue Biopharma Correlation. Cue |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cue Biopharma. If investors know Cue will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cue Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.91) | Revenue Per Share 0.172 | Quarterly Revenue Growth 0.923 | Return On Assets (0.52) | Return On Equity (1.39) |
The market value of Cue Biopharma is measured differently than its book value, which is the value of Cue that is recorded on the company's balance sheet. Investors also form their own opinion of Cue Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Cue Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cue Biopharma's market value can be influenced by many factors that don't directly affect Cue Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cue Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cue Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cue Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Depreciation And Amortization Analysis
Compare Cue Biopharma and related stocks such as Coya Therapeutics, Common, Lantern Pharma, and Fennec Pharmaceuticals Depreciation And Amortization Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| COYA | 704.7 K | 704.7 K | 704.7 K | 704.7 K | 704.7 K | 704.7 K | 704.7 K | 704.7 K | 704.7 K | 704.7 K | 704.7 K | 16.1 K | 27.4 K | 24.6 K | 23.4 K |
| LTRN | (2.5 K) | (2.5 K) | (2.5 K) | (2.5 K) | (2.5 K) | (2.5 K) | (2.5 K) | (2.5 K) | (2.5 K) | 1.6 K | 3.4 K | 97.4 K | 154.7 K | 174.8 K | 183.6 K |
| FENC | 52 K | 43 K | 20 K | (1000) | (699 K) | (1.2 M) | (88 K) | 134 K | 521 K | 64 K | 402 K | 17.2 M | 149 K | 287 K | 272.6 K |
| ANIX | 100 K | 7.2 K | 125 | 314.5 K | 337.8 K | 358.6 K | 368.5 K | 343.7 K | 885.1 K | 90.2 K | 59.9 K | 42 K | 46 K | 52.9 K | 50.3 K |
| INMB | 50 K | 50 K | 50 K | 50 K | 50 K | 50 K | 50 K | (150 K) | (3.1 M) | (3.1 M) | 12.2 M | (1.2 M) | (1.3 M) | 29.7 M | 31.2 M |
| INAB | 96 K | 96 K | 96 K | 96 K | 96 K | 96 K | 96 K | 96 K | 96 K | 164 K | 96 K | 251 K | 1.1 M | 1.8 M | 1.9 M |
| PYPD | 60 K | 60 K | 60 K | 71 K | 108 K | 108 K | 127 K | 205 K | 411 K | (10.7 M) | 1 M | 1.1 M | 1.7 M | 1.8 M | 1.9 M |
| XFOR | 389 K | 389 K | 389 K | 389 K | 389 K | 389 K | 285 K | 195 K | 155 K | 7.8 M | 351 K | 1.9 M | 2 M | 419 K | 398.1 K |
| TERN | 65 K | 65 K | 65 K | 65 K | 65 K | 65 K | 65 K | 65 K | 65 K | 195 K | 394 K | 512 K | 1 M | 292 K | 456.5 K |
| DAWN | (2 K) | (2 K) | (2 K) | (2 K) | (2 K) | (2 K) | (2 K) | (2 K) | (2 K) | (2 K) | 155 K | 199 K | 531 K | 383 K | 278.5 K |
| HOOK | 398 K | 398 K | 398 K | 398 K | 398 K | 398 K | 398 K | 398 K | 640 K | 1.4 M | 4.2 M | 4.6 M | 3.6 M | 3.6 M | 2.9 M |
| CGTX | 14.3 M | 14.3 M | 14.3 M | 14.3 M | 14.3 M | 14.3 M | 14.3 M | 14.3 M | 14.3 M | 14.3 M | 98 K | 93 K | 235 K | 252 K | 239.4 K |
| TFFP | 206.3 K | 206.3 K | 206.3 K | 206.3 K | 206.3 K | 206.3 K | 206.3 K | 206.3 K | 206.3 K | 206.3 K | 206.3 K | 111.5 K | 388.2 K | 502.5 K | 332.3 K |
| TCRX | 519 K | 519 K | 519 K | 519 K | 519 K | 519 K | 519 K | 519 K | 519 K | 519 K | 1.2 M | 3.3 M | 5.1 M | 5.4 M | 3.4 M |
Cue Biopharma and related stocks such as Coya Therapeutics, Common, Lantern Pharma, and Fennec Pharmaceuticals Depreciation And Amortization description
The systematic reduction in the recorded value of an intangible asset. This includes the allocation of the cost of tangible assets to periods in which the assets are used, representing the expense related to the wear and tear, deterioration, or obsolescence of physical assets and intangible assets over their useful lives.My Equities
My Current Equities and Potential Positions
| Cue Biopharma | CUE |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Massachusetts; U.S.A |
| Exchange | NASDAQ Exchange |
USD 1.01
Check out Cue Biopharma Performance and Cue Biopharma Correlation. For information on how to trade Cue Stock refer to our How to Trade Cue Stock guide.You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Cue Biopharma technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.